Notch is out — your watchlist beside the MacBook notch, synced with this account.
Learn more ↗We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Avalo Therapeutics, Inc.는 임상 단계 생명공학 기업으로, 미국에서 면역 매개 염증성 질환에 대한 IL-1ß 기반 치료제를 개발합니다. 주요 제품인 AVTX-009는 인터루킨-1ß에 결합하는 인간화 단일클론 항체로, 염증성 질환 치료를 위한 2상 임상 시험이 진행 중입니다. 이 회사의 이전 사명은 Cerecor Inc.였으며, 2021년 8월 Avalo Therapeutics, Inc.로 사명을 변경했습니다. Avalo Therapeutics, Inc.는 2011년에 설립되었으며, 펜실베이니아주 웨인에 본사를 두고 있습니다.
